Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

KPV peptide: does it work, is it legal, and what does it cost?

Anti-inflammatory fragment of the hormone alpha-MSH; mouse colitis data, no human trial; topical and oral use in HHS's October 2026 draft policy.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about KPV
Does it work in people?Evidence: Animal-only evidence

No randomized human trial of this peptide; the grade rests on animal and lab studies. See the evidence

Is it legal?Regulatory: HHS interim policy (draft)

Not FDA approved. HHS's draft policy covers single-ingredient compounding under strict conditions. Blends are not covered. [9] [10] See legal status

What does it cost?No FDA approved product and no verified compounded price. Insurance does not cover it. See cost by channel
Side effects?No systematic human safety data. No toxicity reported at the doses used in mouse studies. Injection site reactions reported anecdotally. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is KPV?

KPV is the three amino acid tail fragment of alpha-MSH, a natural skin darkening hormone, that keeps the parent hormone's anti-inflammatory activity without its pigmentation effects. In mouse models of colitis (an inflamed colon), oral KPV reduced inflammation, weight loss, and tissue damage seen under the microscope, and in cell studies very low (nanomolar) concentrations block NF-kB signaling, a main switch for inflammation. No human trial exists, so its evidence grade is animal-only. It was on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 2026 Pharmacy Compounding Advisory Committee meeting on adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), FDA's drug center recommended against listing and the committee voted in favor, according to HHS. On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient KPV on the skin or by mouth only on a patient-specific prescription, under strict quality and reporting conditions. The draft policy is not an FDA approval, does not add KPV to the bulks list, and does not change its evidence grade.

KPV is a synthetic tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-melanocyte stimulating hormone (alpha-MSH). It is also known as Lys-Pro-Val, alpha-MSH (11-13), alpha-MSH C-terminal tripeptide, lysine-proline-valine, KPV peptide, KPV tripeptide.

How does it work?

KPV is taken into intestinal epithelial and immune cells by the PepT1 di/tripeptide transporter, which is induced in the colon during inflammatory bowel disease. Inside cells it inhibits activation of NF-kB and MAP kinase pathways and reduces secretion of pro-inflammatory cytokines. Unlike full length alpha-MSH, KPV does not require the melanocortin-1 receptor for its anti-inflammatory effect (it worked in mice lacking a functional MC1 receptor) and does not stimulate pigmentation. These mechanisms are from cell and mouse studies.

Key facts
ClusterTissue repair and healing
RoutesOral capsule (as sold); Subcutaneous injection (as sold); Topical cream and nasal spray (as sold); Oral in drinking water and intraperitoneal (mouse studies)
Conditions studiedInflammation and inflammatory bowel disease; Inflammatory bowel disease (Crohn disease and ulcerative colitis); Autoimmune disease
Recordv3, reviewed, verified Nov 1, 2026

KPV peptide benefits: what the evidence shows

Evidence: Animal-only evidenceGrade assigned per the methodology.

Two independent 2008 mouse studies showed that KPV reduces intestinal inflammation. Oral KPV in drinking water reduced the incidence and severity of DSS and TNBS induced colitis with lower pro-inflammatory cytokine expression, and in DSS and T cell transfer colitis KPV led to earlier recovery, regained body weight, reduced inflammatory infiltrates, and lower myeloperoxidase activity. Later mouse work from one of the same groups found that KPV reduced colitis associated tumor formation and that KPV packaged in targeted nanoparticles eased colitis. No indexed human trial of KPV for any indication has been published.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials0n/a
Human observational studies0n/a
Animal studies4n/a
All indexed studies4n/a

Human evidence

No indexed human trial identified. KPV is sold for inflammatory bowel symptoms, skin inflammation, and general anti-inflammatory use on the strength of mouse data and the known biology of alpha-MSH; no human dose finding, safety, or efficacy study has been published.

Animal evidence

In mice, KPV added to drinking water reduced DSS and TNBS induced colitis, with lower histologic damage and pro-inflammatory cytokine mRNA; the effect was mediated by PepT1 uptake. In a second laboratory, KPV in DSS colitis produced earlier recovery and significantly stronger regain of body weight, reduced inflammatory infiltrates and myeloperoxidase activity, and also produced recovery in CD45RB(hi) T cell transfer colitis; it rescued all animals in the treatment group of mice lacking a functional MC1 receptor, showing the effect is independent of that receptor. In a mouse model of colitis associated cancer, KPV prevented tumor formation in normal mice but not in mice lacking PepT1, and oral KPV delivered in hyaluronic acid coated nanoparticles reduced mucosal damage and TNF-alpha in mouse ulcerative colitis.

Key studies

Indexed studies of KPV
StudyDesign and populationOutcomeGrade
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation2008 PMID 18061177In vitro epithelial and T cell assays plus DSS and TNBS induced colitis in miceHuman intestinal epithelial and T cell lines; mice with chemically induced colitisNanomolar KPV inhibited NF-kB and MAP kinase signaling and cytokine secretion via PepT1 uptake; oral KPV reduced incidence and severity of colitis with lower pro-inflammatory cytokine expressionEvidence: Animal-only evidence
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease2008 PMID 18092346DSS colitis and CD45RB(hi) T cell transfer colitis in mice, including MC1 receptor deficient miceMice with induced colitisKPV led to earlier recovery, stronger regain of body weight, reduced inflammatory infiltrates and myeloperoxidase activity; effect independent of the MC1 receptorEvidence: Animal-only evidence
Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model2016 PMID 27458604AOM/DSS colitis associated cancer model in wild type, PepT1 overexpressing, and PepT1 knockout miceMiceKPV prevented colitis associated tumor formation in wild type mice but had no effect in PepT1 knockout miceEvidence: Animal-only evidence
Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis2017 PMID 28143741Nanoparticle formulation study plus mouse ulcerative colitis modelMice with induced colitis and cultured colon and immune cellsOral KPV nanoparticles in a hydrogel reduced mucosal damage and TNF-alpha and outperformed a non targeted KPV nanoparticle systemEvidence: Animal-only evidence

Conditions studied

Conditions with evidence for KPV
ConditionGradeNote
Inflammation and inflammatory bowel diseaseEvidence: Animal-only evidenceAlpha-MSH fragment; reduced colitis in mouse models; FDA's drug center recommended against 503A listing and the advisory committee voted in favor (HHS policy, Appendix B); HHS's October 2026 draft policy, which is not an approval, covers conditional compounding of the single-ingredient product.
Inflammatory bowel disease (Crohn disease and ulcerative colitis)Evidence: Animal-only evidenceReduced colitis severity and inflammatory cytokines in mouse models, including when given orally; no human study; FDA's drug center recommended against 503A listing and the advisory committee voted in favor (HHS policy, Appendix B); HHS's October 2026 draft policy, which is not an approval, covers conditional compounding of the single-ingredient product.
Autoimmune diseaseEvidence: Animal-only evidenceReduced inflammation in mouse colitis models; no human study.

Is KPV legal in the United States?

Regulatory: HHS interim policy (draft)WADA: WADA prohibited

FDA and compounding status

KPV is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds KPV when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (topical or oral only), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add KPV to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

  1. HHS

    HHS draft policy lets licensed pharmacies compound six peptides without enforcement action

    HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.

  2. PCAC

    FDA advisory committee reviews six peptides; FDA's briefing recommends against listing

    At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.

  3. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  4. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Full tracker for KPV or the category-wide tracker.

Email me when KPV's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of KPV used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Not established in human literature. Mouse colitis studies gave KPV orally in drinking water, in nanoparticles, or by injection; animal doses do not translate to a human dose, and no human study has been published.

Routes reported

Routes of administration reported for KPV
#Route
1Oral capsule (as sold)
2Subcutaneous injection (as sold)
3Topical cream and nasal spray (as sold)
4Oral in drinking water and intraperitoneal (mouse studies)

KPV side effects

Side effects

Side effects reported for KPV
#Reported side effect
1No systematic human safety data
2No toxicity reported at the doses used in mouse studies
3Injection site reactions reported anecdotally
4Because it dampens NF-kB driven immune signaling, a theoretical concern about impaired response to infection exists (not demonstrated)

Interactions

Interactions reported for KPV
#Interaction
1No formal human interaction studies exist
2Theoretical additive immune suppression with corticosteroids, biologics, or other immunosuppressants (not studied)

Contraindications

Contraindications for KPV
#Contraindication
1Active serious infection (theoretical, given immune dampening)
2Pregnancy and breastfeeding (no data)
3Competitive athletes subject to WADA testing (prohibited under S0)

How do people access KPV legally?

Typical cost: No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient KPV on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.

Access options

  • Conditional

    Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient KPV on the skin or by mouth only on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.

  • Not available

    Not available as an FDA approved product.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare KPV

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [11] [12] [13]

In October 2026, HHS released a draft policy saying it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds KPV as a single-ingredient product in topical or oral forms only, on a patient-specific prescription, from an FDA-registered manufacturer with a tested certificate of analysis. It is not an FDA approval and does not put KPV on the 503A bulks list; the policy is not binding, and HHS may revisit it. Blends that mix KPV with other peptides are not covered, and state rules still apply. [9] [10]

What FDA found

  • July 2026: FDA's review found websites offering KPV from compounding pharmacies through telemedicine and online consultations, as injectable, oral, topical, and nasal products and in mixes with other peptides. [14]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [11] [15] [16] [17] [18] [19]

What that means for you

  • A pharmacy that compounds KPV relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [10]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [19]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [20]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [21] [22]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [17]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, KPV is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [5]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [19]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [24] [25]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [13] [25] [26]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [19] [27] [28] [29] [30] [31]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [19]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [13]
  • Pharmacy: Is this made for me on a prescription written in my name? [26]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [13] [25]
  • Prescriber: What is the legal basis for a pharmacy to compound KPV? Is it FDA approved or on the 503A bulks list? [3] [19]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [13]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [20]

Blends that contain KPV

KPV is sold in a premixed blend under the name below. No blend has been tested as a combination, and a mix is only as lawful as its least lawful ingredient.

  • KLOW: with GHK-Cu, BPC-157, TB-500. No federal basis to compound.

All peptide blends

Frequently asked questions

What is KPV peptide?

KPV is a three amino acid peptide (lysine, proline, valine) cut from the end of alpha-MSH, a natural hormone. It keeps the hormone's anti-inflammatory activity without darkening skin, and it is studied mainly for gut inflammation. It is not an FDA approved drug, and PeptideAgent grades its evidence animal-only because no human trial has been published. [1] [2]

KPV peptide benefits: what does the evidence show?

In mice, oral KPV reduced chemically induced and T cell driven colitis in two independent 2008 studies, with less weight loss, less tissue damage, and lower inflammatory cytokines. Later mouse work found it prevented colitis associated tumors and that targeted KPV nanoparticles eased colitis. All of this is animal-only evidence: no human trial of KPV for gut, skin, or any other condition has been published, so its benefits in people are unproven. [1] [2] [6] [7]

What are the side effects of KPV?

There is no systematic human safety data. Mouse studies did not report toxicity. Anecdotal reports mention injection site irritation for the injectable form. Because KPV suppresses NF-kB driven inflammatory signaling, a theoretical concern about blunted responses to infection exists but has not been studied. Unlike full length alpha-MSH or melanotan peptides, it does not darken skin. [1] [2]

Oral KPV vs injection: what did studies use?

The mouse colitis studies mostly gave KPV by mouth, in drinking water or in nanoparticles designed to reach the colon, because gut cells take it up through the PepT1 transporter that inflammation switches on. Products are also sold as injections, creams, and nasal sprays, none of which has been studied in people. No human dose has been established for any route. [1] [7]

Is KPV FDA approved?

No. KPV is not FDA approved for any use. It was on the 503A Category 2 list from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 23, 2026 Pharmacy Compounding Advisory Committee meeting, FDA's drug center (CDER) recommended against adding it to the 503A bulks list and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient KPV on the skin or by mouth only on a patient-specific prescription, under strict quality and reporting conditions. That is not an FDA approval or a bulks listing, it is not binding, and HHS may revisit it. Products sold as research chemicals or supplements for human use are still unapproved drugs. [3] [4] [8] [9] [10]

Is KPV banned by WADA?

Yes, by default. KPV is not named on the WADA Prohibited List, but it has no approval from any government health authority for human use, so it falls under section S0 (non-approved substances) and is prohibited at all times. Athletes subject to testing should not use it. [5]

KPV vs BPC-157: which is better for gut healing?

Neither has human trial data. BPC-157 has a larger rodent literature covering ulcers, fistulas, and NSAID injury, while KPV has two mouse colitis studies focused on immune driven inflammation rather than tissue repair. Both were on the FDA Category 2 list until their nominations were withdrawn in April 2026, and at the July 2026 committee meeting FDA's drug center recommended against listing either while the committee voted in favor (HHS policy, Appendix B). Both are in HHS's October 2026 draft enforcement discretion policy, which covers single-ingredient products only. They are often sold together, a combination never tested in humans and not covered by that policy. [1] [4] [10]

Is KPV the same as alpha-MSH or melanotan?

No. KPV is only the last three amino acids of alpha-MSH. It keeps the anti-inflammatory activity but, in mice, works without the melanocortin-1 receptor, so it does not cause the tanning that alpha-MSH and the melanotan peptides do. It is a different compound with a different (and much smaller) evidence base. [2]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008PubMed 18061177, 2008
  2. [2]Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008PubMed 18092346, 2008
  3. [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  4. [4]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  5. [5]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  6. [6]Viennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016PubMed 27458604, 2016
  7. [7]Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther 2017PubMed 28143741, 2017
  8. [8]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  9. [9]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026
  10. [10]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history)2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, November 1). KPV: evidence, legality, and access. https://peptideagent.ai/peptides/kpv
HTML link
<a href="https://peptideagent.ai/peptides/kpv">KPV: evidence, legality, and access</a>, PeptideAgent, updated November 1, 2026.